01—Abstract
Summary
Summary of the 10-K/A filed April 3, 2014. Cited figures are marked; the original filing is the authoritative source.
Bristol-Myers Squibb Company (BMY) filed an amendment to its 2013 Form 10-K on April 2, 2014, primarily to re-file a revised redacted version of an exhibit related to a confidential treatment request.
This amendment does not alter any other disclosures or financial information from the original filing on February 14, 2014. Therefore, investors should refer to the original 10-K for a comprehensive understanding of BMY's financial performance, strategic initiatives, and risk factors for the fiscal year ended December 31, 2013.
The original filing indicated BMY's status as a large accelerated filer and a well-known seasoned issuer, with significant market capitalization as of June 30, 2013. Investors should consult the original February 14, 2014 filing for detailed financial statements, management's discussion and analysis, and other critical information pertinent to the company's operational and financial health during that period.
02—Key points
Key Highlights
- This filing is an amendment (10-K/A) to the original Form 10-K filed on February 14, 2014.
- The sole purpose of this amendment is to re-file a revised redacted version of Exhibit 10x due to changes in a confidential treatment request.
- No other changes have been made to the original filing or any other exhibits.
- The amendment does not reflect events occurring after the original filing date and does not modify or update disclosures affected by subsequent events.
- Bristol-Myers Squibb Company was a large accelerated filer and a well-known seasoned issuer as of the 2013 fiscal year-end.
- The aggregate market value of the company's common stock held by non-affiliates was approximately $73.5 billion as of June 30, 2013.
- Investors should refer to the original February 14, 2014 filing for all substantive financial and operational information.
03—One dollar
04—Financials
Financial Highlights
Figures from 10-K/AFY2013filed April 3, 2014Financial Statements
FY2013 against FY2012
| Line item | FY2013FY2012 | Change |
|---|---|---|
| Revenue | $16.39B$17.62B | −7.0% |
| Cost of Revenue | $4.62B$4.61B | +0.2% |
| Gross Profit | $11.77B$13.01B | −9.6% |
| R&D Expenses | $3.73B$3.90B | −4.4% |
| SG&A Expenses | $4.94B$4.22B | +17.0% |
| Operating Expenses | $13.49B$15.28B | −11.7% |
| Interest Expense | $199.00M$182.00M | +9.3% |
| Net Income | $2.56B$1.96B | +30.8% |
| EPS (Basic) | $1.56$1.17 | +33.3% |
| EPS (Diluted) | $1.54$1.16 | +32.8% |
| Shares Outstanding (Basic) | 1.64B1.67B | −1.6% |
| Shares Outstanding (Diluted) | 1.66B1.69B | −1.5% |
05—Questions
Frequently Asked Questions
What is the primary reason for this amended filing?
The primary reason for this amended filing (10-K/A) is to re-file a revised redacted version of Exhibit 10x, reflecting changes to the Company's confidential treatment request related to that exhibit. No other financial or operational information from the original filing has been changed.
Does this amendment provide new financial information or updates for 2013?
No, this amendment does not provide new financial information or updates. It explicitly states that no other changes have been made to the original filing and it does not reflect events occurring after the original filing date of February 14, 2014.
Where can I find the complete financial and operational details for Bristol-Myers Squibb for the 2013 fiscal year?
Investors should refer to the original Form 10-K filing for Bristol-Myers Squibb Company, filed on February 14, 2014. This amended filing only contains a minor correction to an exhibit and does not contain substantive financial or operational disclosures.
What is Bristol-Myers Squibb's filing status as indicated in this document?
Bristol-Myers Squibb Company is indicated as a large accelerated filer and a well-known seasoned issuer. The aggregate market value of its common stock held by non-affiliates was approximately $73.5 billion as of June 30, 2013.
06—Continue